Foreword by the EBMT President
As we reflect on 2024, I am filled with immense pride and gratitude for the huge dedication and collaborative spirit that define our EBMT community. This year has been marked by significant milestones and advancements that have strengthened our mission to improve patient outcomes in haematopoietic cell transplantation (HCT) and cellular therapy (CT).
Science

EBMT continues its commitment to continually advance the delivery of excellence in scientific research and education, both in the traditional but necessary face-to-face setting and in the online format. The number of publications from the EBMT Working Parties (WPs) and their corresponding impact factors have steadily increased over the years, together with the participation in international meetings and the achievements of significant milestones ... Read more.
Education

The EBMT has launched a dedicated Education Department, strengthening its commitment to advancing excellence in HCT and Cellular Therapy through a structured core curriculum, expanded online learning, and global collaborations. Key initiatives include the EBMT Exam, educational workshops, and the Open Access EBMT Library, ensuring continuous professional development and knowledge-sharing across the field ... Read more.
Patient Care & Advocacy

Improving the care of our patients is a critical objective of the EBMT. We believe in empowering, advocating and amplifying the interests of patients, survivors, and caregivers worldwide. Be sure to catch up on the activities of the Nurses Group, JACIE and the GoCART Coalition throughout this past year.
Financial Report & Highlights 2024
In 2024, income of EBMT continued to grow. For the second year in a row, revenue generated through post-authorisation safety (PAS) studies and pharmaceutical industry-initiated and/or partnered projects represented the largest source of income. Other sources of income are the Annual Meeting, corporate sponsorships, accreditation fees, grants, and investment income...Read more
